What is survodutide?

Survodutide is an experimental once-a-week drug that switches on two receptors, GLP-1 and glucagon. It is studied for obesity and for MASH, a liver disease where fat builds up in the liver and causes swelling and damage, beyond simple fatty liver. This site's review found 3 studies in people for it, covering 387 people. It is not FDA approved anywhere.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of glp-1 and metabolic peptides. Semaglutide, tirzepatide, retatrutide, and the rest of the incretin and glucagon receptor family.